A review of 50 consecutive cytology cell block preparations in a large general hospital

Frederick Mayall, Bridget Chang, Ann Darlington

Abstract

Aims—To review consecutive cell block preparations of cytological specimens in a large general hospital.

Methods—50 cell blocks were made over an 18 month period in which about 1900 fine needle aspirations (FNAs) were performed. The aspirator was a cytologist or, for image guided FNAs, a radiologist with a cytologist at hand to collect the specimen. Forty eight cell blocks were from FNAs and two were from serous fluids.

Results-The cellularity of the cell blocks was inadequate in only four preparations. The main motive for making cell blocks was to obtain tissue for immunohistochemistry. This was performed on 28 cases and a total of 107 immunostained sections were produced. The most common diagnostic dilemma was between carcinoma and melanoma, and the second most common between carcinoma and lymphoma. Consequently cytokeratin, S-100, and LCA were the most frequently used antibodies. At least one of these three antibodies was positive in 17 cases. Five cases were immunostained only for prognostic breast markers.

Conclusions-The use of cell block immu-

nohistochemistry is a reliable and techni-

cally unsophisticated aid in the cytological

examination of tumours other than lym-

phomas. Success depends on having

highly experienced aspirators that reliably

obtain sufficiently cellular material.

(7 Clin Pathol 1997;50:985-990)

Pathology, Waikato Hospital, Hamilton, New Zealand Correspondence to:

Department of

Dr Mayall, Department of Pathology, Waikato Hospital, Private Bag 3200, Hamilton, New Zealand; email: mayallf@hwl.co.nz

Accepted for publication 2 September 1997

Table 1 Primary antibodies. Their sources, dilutions, and enhancement methods

Antibody	Source	Dilution	Enhancement
Cytokeratin (CAM 5.2)	Becton Dickinson	Prediluted	Microwave
S100	Dako	1/1500	Microwave
Carcinoembryonic antigen (CEA)	Dako	1/200	Microwave
Ber EP4	Dako	1/100	Trypsin
Prostate specific antigen (PSA)	Dako	1/30	Microwave
HMB-45	Dako	1/25	Microwave
Leucocyte common antigen (LCA)	Dako	1/400	Microwave
CD20	Dako	1/200	Microwave
CD43	Dako	1/200	Microwave
Kappa light chain (K)	Novocastra	1/100	Trypsin
Lambda light chain (L)	Dako	1/50	Microwave
p53	Dako	1/25	None & microwave
Oestrogen receptor (ER)	Novocastra	1/50	Microwave
Progesterone receptor (PR)	Novocastra	1/40	Microwave
c-erb-B2	Dako	1/900	Microwave
Thyroglobulin (TG)	Dako	1/100	Microwave
a Feto protein (aFP)	Dako	1/500	Microwave
Desmin	Dako	1/400	Microwave
Smooth muscle actin (SMA)	Dako	1/40	Microwave
CD34	Novocastra	1/25	Microwave
Factor VIII (F VIII)	Dako	1/1000	Microwave

Becton Dickinson, Mountain View, California, USA; Dako, High Wycombe, Bucks, UK; Novocastra, Newcastle upon Tyne, UK

Keywords: cell block; immunohistochemistry; fine needle aspiration cytology; audit

Cytology cell blocks are made by centrifuging cytology specimens to form solid pellets. Paraffin wax embedded sections can be cut for haematoxylin and eosin histology and special stains, including immunohistochemistry. This study reviewed 50 consecutive cell block preparations of cytological specimens in a large general hospital.

Patients and methods

The vast majority of cell block specimens were obtained from fine needle aspirations (FNAs). These were performed as part of a near-patient rapid diagnosis FNA service. A second FNA was used to collect the specimen for the cell block after the initial diagnosis had been made on the first specimen. The image guided FNAs (17 cases) were performed by a consultant radiologist with a cytologist at hand to collect the specimen. A variety of needles was used depending on the site. The manually guided FNAs (31 cases) were performed with a 23 gauge 3.75 cm needle using a "needle only" technique and the operator was always a consultant pathologist with a special interest in FNA cytopathology. Maximum material was collected by extensive agitation of the needle in the lesion. Ten per cent formal saline was drawn up though the needle into an attached syringe and then gently ejected back into a specimen container.

CELL BLOCKS

Serous fluids were prepared by centrifuging at $1270 \times g$ for seven minutes, discarding the supernatant, and resuspending in formalin. After at least an hour of fixation the suspension of the FNA specimen in formalin or the resuspension of the serous fluid was centrifuged at 1270 $\times g$ for seven minutes. The supernatant formalin was decanted off. The deposit was resuspended in molten 0.9% agar at 50°C and quickly placed in a centrifuge again. It was spun at 1270 $\times g$ for two minutes and then refrigerated at 4°C for 30 minutes to harden the agar. The excess agar was trimmed to leave a cell button. This was wrapped in tissue paper and placed in a plastic cassette for paraffin processing as for a routine surgical biopsy specimen. A haematoxylin and eosin stained section was cut from each cell block and examined. Any further stains were then requested and performed.



Figure 1 A cell block section from a spinal myeloma deposit showing strong immunostaining for lambda. There was no positivity for kappa.



Figure 2 A cell block section of a thymoma showing immunostaining for cytokeratin (CAM 5.2) in the epithelial cells but not in the smaller lymphocytes.

IMMUNOHISTOCHEMISTRY

Immunohistochemistry was performed on $3 \mu m$ paraffin sections cut on to APES coated slides. Microwave pretreatment was in citrate buffer at pH 6 for 10 minutes at boiling temperature. The sources, dilutions, and incubation times of the primary antibodies are shown in table 1. The incubation time for the primary antibodies was 10 minutes at room temperature. The sections were then developed using a streptavidin-biotin-immunoperoxidase kit (Dako, High Wycombe, Bucks, UK). The chromogen was DAB.

Results

The results are displayed in table 2. These 50 cell blocks were from an 18 month period in which about 1900 FNAs were performed. Forty eight of the 50 cases were FNAs and two were serous fluid specimens. Seventeen of the FNAs were image guided. Most of these were computed tomography guided. Some were fluoroscopically guided FNAs of lung, and a few were ultrasound guided FNAs of the neck.

The cell blocks contained sufficient cells in 46 cases. In 18 cases the cell blocks were not used for immunohistochemistry. In most of these the motive for taking the cell block had been to collect material for immunohistochemistry but then a confident diagnosis was made from conventional cytology alone and immunostaining was not performed. In a few cases, in particular some possible small cell carcinomas of the lung, the cell blocks were taken to see the haematoxylin and eosin stained histology of the cells.

Immunostaining was performed in 28 cases. A total of 107 sections were immunostained and in only one (case 38) were there insufficient cells. None of these sections was inadequate for any other reason. The two most common diagnostic dilemmas for which immunostaining was employed were between carcinoma and melanoma (10 cases) and between carcinoma and lymphoma (nine cases). Cell block immunohistochemistry was performed solely for breast carcinoma prognostic markers (oestrogen receptor, progesterone receptor, and c-erb-B2) in five cases. Breast markers were performed in conjunction with other immunostains in five further cases.

Cytokeratin was used for 21 of the 28 immunostained cases, S-100 on 11 cases, and leucocyte common antigen (LCA) for nine cases. At least one of these three antibodies was positive for 17 cases. Cytokeratin was used on every occasion that one or both of the other two were used. These three antibodies were used far more than any others except for prognostic breast markers (10 cases). The largest number of immunostains done on one cell block was eight. Twenty one different antibodies were used in total; seven being used only once. A diastase periodic acid-Schiff stain was also used on two cases.

Cell blocks were not usually performed on tumours that appeared to be lymphoid in the smears as the material obtained from the second aspirate was usually used for immunolabelled flow cytometry instead. There were 24 FNA samples taken for lymphoid marker flow cytometry during the period studied. Consequently the cell block cases for which lymphoid immunostains were positive tended to be unusual lymphoid neoplasms or other tumours. These included a myeloma deposit in the spine (fig 1), a high grade T cell lymphoma, a thymoma (fig 2), and a high grade B cell lymphoma.

Cell blocks were taken from six possible small cell carcinomas. In three of these cases only haematoxylin and eosin stained sections were cut but immunostains for cytokeratin and LCA were performed on three, and were positive for cytokeratin in two. The third (case 38) had insufficient cells in the immunostained sections. In the other 27 cases the results of the immunohistochemistry either confirmed the cytological diagnosis that had been suggested in the provisional report issued at the time of the aspirate or, in a few cases, indicated the correct diagnosis from a choice of two or more that were being considered. One example of the latter was lymphoma versus thymoma in case 37. The immunolabelled flow cytometry for lymphoid markers showed this tumour to be composed almost exclusively of T cells but the



Figure 3 A cell block section of a leiomyosarcoma showing immunostaining for smooth muscle actin.

strong cytokeratin positivity in a minority of cells in the cell block allowed the correct diagnosis to be made. A second example (case 34) was the diagnosis of metastatic signet ring carcinoma in the neck of a woman with a previous angiosarcoma of the head. A third example (case 43) was the diagnosis of metastatic breast carcinoma in the axilla of a middle aged woman who already had metastatic melanoma in the lymph nodes of her neck.

All lymphomas were positive for LCA. All carcinomas were positive for cytokeratin except case 38. All melanomas were positive for S-100 except case 11 and it was positive for HMB-45. These results are indicative of the high quality of antigen expression in the cell block tissue. The strong positivity for lambda light chain in the spinal deposit of myeloma is another example (fig 1). None of the diagnoses made in the 50 cases was contradicted by subsequent investigations or follow up.

Discussion

The high cell block adequacy rate can be attributed to a cytologist performing or supervising a re-aspiration of the lesion for the sole purpose of collecting material for a cell block rather than dividing the first aspirate in two. A previous study reported satisfactory division of single aspirates into smears and cell block material when a relatively large (21 gauge) needle is used.¹ It could be argued that one large gauge needle is no more painful than two small ones except that we only made a second pass to collect cell block material in 50 of about 1900 FNAs. The ability to perform a second aspirate for a cell block in appropriate cases depends on a cytologist being available for near-patient reporting of the first aspirate. Success depends on the high cellularity of the aspirate.

In general the cell blocks that did not have any further special stains did not contribute to the diagnosis. This appears to conflict with previous reports. Brown *et al* described a study in which the examination of 84 FNAs revealed 55 malignancies with cytology alone but a further nine malignancies were identified on examining the cell blocks.² This was not our experience but our study was fundamentally different in that we examined the cytology specimens immediately and if they did not contain sufficient material for a definite diagnosis the FNA was repeated and more smears examined. In the study by Brown et al the cytology smears and the material for the cell blocks seem to have been sent away to the laboratory for examination and there was no opportunity to repeat the aspirate if the smears were not diagnostic. A study by Flint on cytology and cell blocks from 111 bronchial washings found 52 malignancies in the cytological preparations and 43 in the cell blocks.³ Four of the "malignant" cell blocks were negative for malignancy on cytology. We did not examine any bronchial washing cell blocks in our study.

The dominance of cytokeratin, S-100, and LCA use reflects the importance of cell block immunostaining in distinguishing between carcinoma and melanoma and between carcinoma and lymphoma. These were by far the most common diagnostic dilemmas to be encountered.

One of the principal advantages of immunostaining cell blocks over immunostaining smears is that a large battery of stains can be easily done on the former. This is exemplified by case 41 (fig 3) in which eight different immunostains were used. It would be difficult to make eight spare smears for immunocytochemistry from a single FNA sample.

Another advantage of cell block immunohistochemistry is that it requires no special techniques or equipment and so it may be readily adopted by small laboratories that are able to perform immunohistochemistry on paraffin wax sections of histology specimens but would only occasionally need to immunostain cytological specimens.

Kung et al reviewed some other advantages of cell block immunostaining over immunocytochemistry of unstained or destained sections.¹ Storage of cell blocks is easier than unstained slides. Freezing is not necessary and there is only minimal deterioration in the antigenicity with time. Destaining cytology slides is labourious and results in the loss of what may be the only conventionally stained cytological material. In addition, the results from immunostaining smears tend to be poor unless the procedure is frequently practised. In particular there tends to be a high level of background staining. This is sometimes due to technical artefact, but even with the best technique heavy background staining often occurs, probably because of non-specific staining of thick clumps of cells and proteinaceous debris. It has been claimed that ThinPrep (Cytyc Corp, Boxborough, Massachusetts, USA) type smears reduce background staining by producing an even deposit of cells that have been washed in buffer.⁴ Our own experience has been that the use of an alkaline phosphatase staining method rather than an immunoperoxidase method greatly reduces background staining in immunostained smears.⁵

preparations
block
cell
consecutive
50
of
Details
Table 2

					Antibe	бр										
Specimen type	FNA	Initial diagnosis	Cells	IHC	CAM 5.2	S100	L CEA I	Ber EP4 PSA I	HMB45 LCA	CD20 CD43	KLP	53 ER	PR B2	TG AFP min	F SMA CD34 VIII	DPAS Final diagnosis
1 FNA left axills 2 FNA right nec	k M	Melanoma Small cell carcinoma	* *	z >	+	1	i	1								Melanoma Small cell
3 FNA left avilla	Z	Somemons carcinoma	>	>	+	I	ł.	I								carcinoma Squamous
		od antions carcinoma	•	•	-											carcinoma
4 FNA rib 5 FNA lung	пп	Carcinoma, Prostate Small cell carcinoma	**	≻Z				I								Small cell
6 FNA breast	W	Breast carcinoma	Y	Y								+	+			carcinoma Breast
:	;		;	;												Carcinoma
7 FNA scalp 8 FNA breast	ΣZ	Carcinoma Breast carcinoma	х×	ΖZ												Breast carcinoma
9 FNA breast	W	Breast carcinoma	Y	z												Breast carcinoma
10 Pleural fluid	ΧX	Carcinoma, ?thyroid Melonoma	×	7 >	1	,	I							ł		+ Adenocarcinoma Melanoma
11 FINA neck 12 FNA axilla	Σ	Metallollia Breast carcinoma	- Y	ł	1	1			_			1	I L			Breast
13 FNA breast	W	Breast carcinoma	Y	Υ								1	1			Breast
14 FNA breast	W	Breast carcinoma	z	z												Breast
15 FNA breast	W	Breast carcinoma	Y	Υ								+	+			carcinoma Breast
			:	;												carcinoma I muchomo
 Ascitic fluid FNA breast FNA adrenal 	I Y S	Malignancy Melanoma Melanoma	* * *	***	1 1 1	ı + +			+			1				Lympnoma Melanoma Melanoma
19 FNA abdomer	I	Carcinoma, ?renal	z	z												Carcinoma, Prenal
20 FNA neck	W	Breast carcinoma	z	z												Breast carcinoma
21 FNA liver	Ι	Hepatocellular carcinoma	Y	Υ	+									I	1	Hepatocellular carcinoma
22 FNA liver	Ι	Carcinoma, ?squamous	Y	z												Carcinoma, Decrugaments
23 FNA subcutis	W	Breast carcinoma	Y	Z												Breast
24 FNA breast	W	Breast carcinoma	Y	Υ	+	+			1			Ι	-			Breast
25 FNA lung	I	Inflammatory mass	Y	Z												Inflammatory
26 FNA spine		Carcinoma or myeloma	× ۲	7	ł				+	+	+ 1					mass Myeloma Hepatocellular
21 FINALIVE			- >	2 2												carcinoma Thrombus
28 FINA intracardiac	-	I IITOINOUS	I	Z												
29 FNA lung	I	Small cell or adenocarcinoma	Y	Z												Adenocarcinoma
30 FNA	I	Solitary fibrous tumour	Y	Υ	I										1	Sarcoma
31 Pleural fluid	S E	Carcinoma or	Y	Υ	+	I	I				I					Probable mesothelioma
32 FNA neck	W	Lymphoma or carcinoma	Y	Y	I				+	+						T cell lymphoma

System of period Red						Annoo	ty.						
3PolytamNRecurrent fungtionalYYHerent functionalRecurrent functional3FNA netsMagnetermanorYY++Mathetermational3FNA netsMagnetermanorYY++Mathetermational3FNA netsMagnetermanorYY++Mathetermational3FNA netsMagnetor ertificanalYY+-+Stantona3FNA netsMathetermationalYY+-+-Stantona9FNA netsMathetermationalYYP+-Stantona9FNA netsMathetermationalYYP+-Stantona9FNA netsMStantonaYYPStantona9FNA netsMStantonaYYPStantona9FNA netsMStantonaYYP9FNA netsMMathetermanoYY9FNA netsMMathetermanoYY9FNA netsMMathetermanoYY	Specimen type	; Fi	NA Initial diagnosis	Cells	IHC	CAM 5.2	S100	Ber CEA EP4 P	8A HMB45 LCA CD20 CD43 K L p5	C- erb- 13 ER PR B2	Des- TG AFP min	F SMA CD34 VIII	DPAS Final diagnosis
31 Productionand Y Y + + Addocusionand 32 Productionand Y Y + - - - Stationand 33 Productionand Y Y + - - - Stationand Stationand - - Stationand - - - - Stationand Stationand - - - - - - - - - - Stationand	33 FNA arm	N N	I Recurrent lymphoma	Y	Υ	I	1		+				Recurrent
3 FMA neck M Summa section Y Y A And reduction Y Y A Summa section Summa section <td>34 FNA neck</td> <td>N</td> <td>I Angiosarcoma or</td> <td>Υ</td> <td>Υ</td> <td>+</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>I</td> <td>+ Adenocarcinoma</td>	34 FNA neck	N	I Angiosarcoma or	Υ	Υ	+						I	+ Adenocarcinoma
36FNA check will1Symmetric excitionalYN37FNA1Lymphora e tryinoualYYYYTynoual38FNA effectiveNSmall cel carcinonalYYYYTynoual39FNA effectiveNSmall cel carcinonalYYYYTynoual30FNA effectiveNSqumous ercinonalYNYYSmall cel carcinona30FNA effectiveNSqumous ercinonalYNYYSmall cel carcinona40FNA effectiveNSqumous ercinonalYYYYSqumous ercinona41FNANMalgrancyYYYYYLipuporal42FNA effectiveNMalgrancyYYYYLipuporal43FNA effectiveNMalgrancyYYYYLipuporal44FNA effectiveNMalgrancyYYYYLipuporal45FNA effectiveNMalgrancyYYYYLipuporal46FNA effectiveNMalgrancyYYYYLipuporal47FNA effectiveNMalgrancyYYYYLipuporal48FNA effectiveNMalgrancyYYYYLipuporal49FNA effectiveNMalgrancyY	35 FNA neck	M	carcinoma I Small cell carcinoma	Y	Y	+			I				Small cell
7FMA1Lymphoma or thynomaYY++++The main or thynoma8FMA neckMSmall cell cercinomaYYYFThe main or thynoma9FMA neckMSmall cell cercinomaYYYFThe main or thynoma9FMA neckMSquanous cercinomaYYNThe main or thynoma9FMA neckMSquanous cercinomaYYN9FMA neckILupphomaYNN40FMA neckILupphomaYY <td>36 FNA chest w</td> <td>'all I</td> <td>Squamous carcinoma</td> <td>Y</td> <td>z</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Squamous</td>	36 FNA chest w	'all I	Squamous carcinoma	Y	z								Squamous
38 Rumantum Rumantum bolic M Standacticationa Y Y F Standactication Y F Standactication Y Rumantum	37 FNA	Ι	Lymphoma or thymoma	Y	Y	+			+ 1 +				Thymoma
30FNA reckMSquarous carcinonaYN40FNAILymphonaSquarous carcinonaYN40FNAILymphonaYNLymphona41FNAILymphonaYYLLymphona42FNANMaigrancyYYNL43FNANMaigrancyYNLLjorghona44FNAMMaigrancyYNHLjorghona45FNA hestMMaigrancyYNHH44FNA hestMMeanona or carcinonaYNHH45FNA hestMBreast carcinonaYNNHH46FNA hugISuandona or carcinonaYNNHH47FNA hugISuandona or carcinonaYNNHH48FNA hugISuandona or carcinonaYNNHH49FNA hugISuandonaYNNNHH46FNA hugISuandonaYNNHHH47FNA hugISuandonaYNNNHHH48FNA hugISuandonaYNNNNHHH49FNA hugISuandonaYY <td>38 FNA neck</td> <td>N</td> <td>I Small cell carcinoma</td> <td>Y</td> <td>Y</td> <td>ц</td> <td></td> <td></td> <td>I</td> <td></td> <td></td> <td></td> <td>Small cell</td>	38 FNA neck	N	I Small cell carcinoma	Y	Y	ц			I				Small cell
	39 FNA neck	M	I Squamous carcinoma	Υ	z								Squamous
	40 FNA abdominal	Ι	Lymphoma	Y	z								Lymphoma
42 FNA axila M Maignancy Y N 43 FNA axila M Maignancy Y N Evest	41 mass 41 FNA abdominal	I	Malignancy	Υ	Υ	I	+	I		1	+	+	Leiomyosarcoma
 FNA axilla M Melanoma or carcinoma Y Y + - FNA breast M Recurrent melanoma Y N FNA breast M Recurrent melanoma Y N FNA breast M Breast carcinoma Y N FNA axilla M Breast carcinoma Y N FNA axilla M Breast carcinoma Y N FNA breast M Breast Carcinoma Y N <li< td=""><td>mass 42 FNA neck</td><td>W</td><td>1 Malignancy</td><td>Υ</td><td>z</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>High grade B</td></li<>	mass 42 FNA neck	W	1 Malignancy	Υ	z								High grade B
41 FNA breast M Recurrent melanoma 45 FNA breast M Breast carcinoma Recurrent melanoma 46 FNA axilla M Breast carcinoma Breast carcinoma 46 FNA axilla M Breast carcinoma Breast carcinoma 47 FNA axilla M Breast carcinoma + + 48 FNA axilla M Breast carcinoma Y N 48 FNA axilla M Melanoma + + + + 48 FNA axilla M Melanoma Y N Melanoma N Melanoma 49 FNA breast M Breast carcinoma Y + + + + Adenocarcinoma 49 FNA breast M Breast carcinoma Y Y + + + H Heinoma 40 FNA breast M Breast carcinoma Y + + + H Hindright factor 41 FNA breast M Lymphoma Y + <td>43 FNA axilla</td> <td>N</td> <td>I Melanoma or carcinoma</td> <td>Y</td> <td>Y</td> <td>+</td> <td>I</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Breast</td>	43 FNA axilla	N	I Melanoma or carcinoma	Y	Y	+	I						Breast
45 FNA breast M Breast carcinoma Breast carcinoma Breast carcinoma 46 FNA axilla M Breast carcinoma Y Y Leiomyosarcom 46 FNA axilla M Breast carcinoma Y Y Leiomyosarcom 47 FNA lung I Small cell or Y N Adenocarcinoma 48 FNA axilla M Melanoma Y N Melanoma 49 FNA axilla M Melanoma Y N Melanoma 49 FNA breast M Breast carcinoma Y Y - - - - 40 FNA breast M Breast carcinoma Y Y -	44 FNA breast	Ň	I Recurrent melanoma	Υ	z								Recurrent
46 FNA axilla M Breast carcinoma Y Y Leiomyosarcom 47 FNA lung I Small cell or Y N Adenocarcinoma 47 FNA lung I Small cell or Y N Adenocarcinoma 48 FNA axilla M Melanoma Y N Melanoma 49 FNA breast M Breast H + + + Erest 49 FNA breast M Breast Breast 50 Pleural fluid M Lymphoma Y Y Cell fymbrona	45 FNA breast	M	I Breast carcinoma	z	z								Breast
48 FNA axilla M adenocarcumua Y N elanoma 49 FNA breast M Breast carcinoma Y Y 49 FNA breast M Breast carcinoma Y Y 50 Pleural fluid M Lymphoma Y Y - + +	46 FNA axilla 47 FNA lung	Ζı	1 Breast carcinoma Small cell or	¥¥	۶Z	I				1		+	Leiomyosarcoma Adenocarcinoma
50 Pleural fluid M Lymphoma Y Y - + + - High grade B cell lymphoma	48 FNA axilla49 FNA breast	ΣΣ	adenocarcinoma 1 Melanoma 1 Breast carcinoma	хX	Z۲					+ + +			Melanoma Breast
	50 Pleural fluid	M	l Lymphoma	Y	Y	I			' + +				High grade B cell lymphoma
	PAS.												

Immunostaining smears does have one notable advantage over cell blocks in that far fewer are needed. This is some times cited as a reason for favouring smear immunostains rather than cell blocks but our study shows that it is almost always possible to obtain sufficient cells from an FNA for cell block immunostaining. A previous study found that 30 of 333 cell blocks had inadequate cellularity.6 However, most of these were thyroid cell blocks, which were not examined in our study.

Fluorescent antibodies can be used as immunolabels for unfixed cytospins and for flow cytometry. The effectiveness of these types of labelling in the FNA diagnosis of lymphomas has been examined and these techniques are quite widely used.⁷ ⁸ They are clearly more effective than cell block immunohistochemistry for characterisation of lymphoid cells, mainly because many lymphoid markers do not survive fixation. However, flow cytometry is not well suited for use with solid tumours as a suspension of single cells is needed. Immunostaining unfixed cytospins of lymphoid lesions has the advantage of requiring far fewer cells than for flow cytometry. However, there is a good deal of technical skill and manual labour involved and it is probably not appropriate for use in centres in which it would be practised only infrequently. In contrast flow cytometry analysis of lymphoid FNAs can be incorporated as a small part of the routine flow cytometry work of a haematology laboratory that consists mainly of bone marrow aspirates and peripheral blood specimens. The high case volume and level of automation makes the analysis cheap and rapid.

Mayall, Chang, Darlington

In conclusion, our study shows that FNAs can reliably obtain cell blocks with sufficient material to be diagnostically useful. The importance of skilled aspirators is evident and we plan to increase the availability of cytologist aspirators with an increase of 0.7 full time equivalents in the consultant pathologist staff in the laboratory. This should help to cover the annual 1400 FNAs workload that has developed since the introduction of the rapid diagnosis FNA service two years ago. We recognise that there are situations in which a cell block is unlikely to contain sufficient tumour cells. In response, the laboratory has recently introduced an immunocytochemistry method that was previously used by one of the authors in another hospital.⁵

- 1 Kung ITM, Chan S, Lo ESF. Application of the immunoperoxidase technique to cell block preparations from fine needle aspirates. *Acta Cytol* 1990;34:297–303.
- Brown K, Fulbright RK, Avitabile AM, Bashist B. Cytologic analysis in fine-needle aspiration biopsy. Am 7 Radiol 1993; 1**61**:629 -31.
- Flint A. Detection of pulmonary neoplasms by bronchial washings. Acta Cytol 1993;37:21-3. 3
- Leung SW, Bedard YC. Immunocytochemical staining on ThinPrep processed smears. Modern Pathology 1996;9: 304 - 6
- Mayall F, Heryet A, Manga D, Kriegeskotten A. p53 immu-5 nostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology. Cytopathology 1997;8:9-11.
- Zito FA, Gadaleta CD, Salvatore C, Filotico R, Labriola A Marzullo A, et al. A modified cell block technique for fine needle aspiration cytology. Acta Cytol 1995;39:93-9
- Chernoff WG, Lampe HB, Cramer H, Banerjee D. The potential clinical importance of fine needle aspiration/flow cytometric diagnosis of malignant lymphoma. J Otolaryngol 1992;21(suppl 1):1-15.
- 8 Hanson CA. Fine-needle aspiration and immunophenotyping: a role in diagnostic histopathology. Am J Clin Pathol 1994;101:555-6.